FDA approves Welireg with pembrolizumab for renal cell carcinoma

FDA approves Welireg with pembrolizumab for renal cell carcinoma

The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear cell component at intermediate-high or high risk for recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated risk of recurrence following surgery. The decision authorizes the use of pembrolizumab (Keytruda), including its subcutaneous formulation (Keytruda Qlex), in combination with belzutifan (Welireg), marking […]